Xcout Intel
Code Biotherapeutics, Inc.
Code Biotherapeutics, Inc. is a biotechnology company headquartered in the Greater Philadelphia area. The firm focuses on next-generation gene therapies and advanced medicine.
Subscribe to see Code Biotherapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Code Biotherapeutics, Inc. at a glance
Code Biotherapeutics, Inc. is a biotechnology company headquartered in United States. Its most recent funding round raised $37.5M in May 2022. Xcout tracks 5 named people at Code Biotherapeutics, Inc., including Alexander Alex Tracy (Chief Technical Officer).
Code Biotherapeutics, Inc. leadership
- Alexander Alex TracyChief Technical Officer
- Brian P. McVeighChief Executive Officer
- Robert C GettsChief Platform Technologies Officer
- Matthew F. RobertsHead of Analytical Methods Development, Chemistry, Manufacturing, and Controls (CMC)
- Paula CarpenterHead of Program Management and Production
Code Biotherapeutics, Inc. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $37.5M | — | |
| Series A | $75M | 1 named | |
| Series A | $10M | 1 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Code Biotherapeutics, Inc. competitors
A few of Code Biotherapeutics, Inc.'s closest competitors — see the full list of competitors and alternatives →
ReCode Therapeutics is a clinical-stage genetic medicines company headquartered in Menlo Park, California, and Durham, North Carolina. The company leverages proprietary delivery systems to power a new class of disease-modifying genetic therapies.
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.
Red Ace Bio is a biotechnology company founded in 2023 to develop next-generation gene therapies targeting lasting cancer remission. The company is headquartered in State College, Pennsylvania.
Prime Medicine, Inc. is an American biotechnology company developing gene therapies based on prime editing. The company is headquartered in Cambridge, Massachusetts.
Gemma Labs Inc. (GEMMABio) is a biotechnology company that develops gene therapies for rare diseases using next-generation AAV technology. The company focuses on programs targeting motor neuron disorders, skeletal conditions, and cardiomyopathies to serve the rare disease community.
Passage Bio, Inc. is a biopharmaceutical company dedicated to pioneering genetic therapies for conditions affecting the central nervous system. Their advanced pipeline includes PBGM01, designed to treat infantile GM1 gangliosidosis by utilizing a proprietary AAVhu68 capsid to deliver a functional GLB1 gene, which codes for the lysosomal acid beta-galactosidase enzyme, to both the brain and peripheral tissues. Another key program, PBFT02, employs an AAV1 capsid to introduce a functional granulin (GRN) gene, encoding progranulin (PGRN), to the brain as a treatment for FTD-GRN. Additionally, PBKR03 is under development for infantile Krabbe disease, leveraging a proprietary AAVhu68 capsid to deliver a functional GALC gene, responsible for producing the hydrolytic enzyme galactosylceramidase, to the brain and surrounding tissues. The company's portfolio also features PBML04 for metachromatic leukodystrophy, PBAL05 for amyotrophic lateral sclerosis, and PBCM06 for Charcot-Marie-Tooth Type 2A. Passage Bio maintains a significant research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program, alongside a development services and clinical supply agreement with Catalent Maryland, Inc. Established in 2017, the company's headquarters are located in Philadelphia, Pennsylvania.
Get Code Biotherapeutics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Code Biotherapeutics, Inc. in Xcout Intel
- 5 named people with titles, LinkedIn and board committees
- 3 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access